Analysis of the individual variability of lipoprotein(a) levels in healthy individuals with elevated lipoprotein(a)

Completed

• Conditions: E78.5; Hyperlipidaemia, unspecified

• Registration Number: DRKS00003974
• Lead Sponsor: niklinik Freiburg Abt. Klinische Chemie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05-16
• Study Completion: 2016-10-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

lipoprotein(a) > 50 mg/dl, no relevant internal diseases, no permanent medication except oral contraceptives

Exclusion Criteria

relevant internal diseases, renal failure, liver failure, hypo-hyperthyreoidism, diabetes mellitus, hormone intake except oral contraceptives, permanent medication

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analysis of lipoprotein(a) serum levels. In the first year once every month, in the second year every third month. The study ends with the last blood sample taken.

Secondary Outcome Measures

Name	Time	Method
In each blood sample (first year once a month, second year every third month) the following parameters are analysed: Cholesterol, Triglycerides, LDL-Cholesterol,VLDL-Cholesterol, HDL-Cholesterol, HDL- and LDL-subtypes, Creatinin,GGT, ALT, AST, Albumin, Cholinesterase,TSH, HbA1c, Lp-PLA2 and lp(a)-subtypes. In test persons who gave consent apo E and apo(a) genotype is analysed.